ABL Diagnostics lifts 2026 revenue outlook to EUR 13.5 million-EUR 14 million

• ABL Diagnostics lifted its 2026 revenue outlook to EUR 13.5 million to EUR 14 million from EUR 12.265 million.
• The new range implies 94.2% to 101.4% growth from 2025 revenue of EUR 6.95 million.
• First-half revenue reached EUR 5.415 million, up 90% year over year, with EBITDA of EUR 1.315 million.
• Guidance revision factors in second-half momentum, with TEXCELL activities contributing following the July 21 takeover.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001942496) on October 01, 2026, and is solely responsible for the information contained therein.